GRI
GRI Bio Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
gri is a development stage biotech company fundamentally changing the way inflammatory disease is treated. gri’s natural killer t (nkt) cell-based therapies are being developed for liver disease and acute liver failure. nkt cells share properties of both nk and t cells and are a functional link between the innate and adaptive immune responses. type 1 nkt cells play a critical role in initiating and propagating the inflammatory response and the hepatic injury that is observed in liver disease. gri’s lead program, gri-0621, is an inhibitor of type i nkt cells and is being developed as a novel oral therapeutic for acute liver failure.
Market Cap: 3.68 Million
Primary Exchange: NASDAQ
Shares Outstanding: 4.52 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.5667789584118212
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 706 trading days
From: 2016-07-29 To: 2019-03-13
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|---|---|---|---|---|---|---|---|
| 2019-12-19 | 2019-12-27 | 2019-12-20 | 2019-01-04 | |||||
| 2019-12-19 | 2019-12-27 | 2019-12-20 | 2019-01-04 | 0.5113 | Cash |
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|